---
title: "AstraZeneca's Datroway extends survival in aggressive breast cancer"
description: "AstraZeneca and Daiichi Sankyo's new breast cancer drug, Datroway, has shown significant promise in extending survival for patients with triple-negative breast cancer. In a late-stage trial, patients "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261745637.md"
published_at: "2025-10-19T06:35:35.000Z"
---

# AstraZeneca's Datroway extends survival in aggressive breast cancer

> AstraZeneca and Daiichi Sankyo's new breast cancer drug, Datroway, has shown significant promise in extending survival for patients with triple-negative breast cancer. In a late-stage trial, patients treated with Datroway had a median overall survival of 23.7 months compared to 18.7 months for those receiving chemotherapy. The drug, which received U.S. approval earlier this year, delivers chemotherapy directly to tumor cells, reducing toxicity. Its success could position it as a competitor to Gilead's Trodelvy, with potential to treat 90% of women with breast cancer.

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 德意志銀行維持對阿斯利康（AZN）的賣出評級 | 德意志銀行分析師 Emmanuel Papadakis 對阿斯利康（AstraZeneca，股票代碼：AZN）維持了賣出評級，目標價為 115.00 英鎊。儘管如此，分析師對阿斯利康的共識評級為強烈買入，平均目標價為 15,292.02 英 | [Link](https://longbridge.com/en/news/276058097.md) |
| 斥資 185 億美元牽手石藥集團後，阿斯利康每股收益預增雙位數 | 阿斯利康預計 2026 年每股收益將實現兩位數增長，腫瘤藥物銷售強勁有望抵消糖尿病藥物專利到期影響。公司近期以高達 185 億美元引入石藥集團長效肽技術，加速佈局 GLP-1 減肥藥市場。儘管面臨美國藥價政策調整，公司通過協議獲得關税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| 貝森特和沃什的 “導師”，德魯肯米勒 Q4“精準” 開倉金融股 ETF、標普等權重 ETF 和巴西 ETF | 科技股方面，德魯肯米勒 Q4 清倉了 Meta，加倉了谷歌與 Sea。德魯肯米勒與貝森特、沃什的 “師徒” 關係讓市場推測，“德魯肯米勒經濟學”——即反赤字、反通脹、反關税——可能通過貝森特和沃什滲透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) |
| “硬件防禦” 對沖 AI 焦慮，蘋果與納指相關性創 20 年新低 | AI 浪潮下，蘋果因未深度捲入軍備競賽，與納指相關性創 20 年新低，成為科技股動盪中的 “避風港”。在 AI 投資回報存疑及軟件業面臨顛覆的焦慮中，蘋果憑藉不易受衝擊的硬件生態逆勢突圍。儘管存在估值偏高及增長放緩壓力，其獨特的 “AI 中 | [Link](https://longbridge.com/en/news/276301841.md) |
| 為 AI 交易 “背書”！OpenAI 正敲定新一輪融資：以 8300 億美元估值募資高達 1000 億美元 | OpenAI 正以 8300 億美元估值推進新一輪融資，目標籌集 1000 億美元。軟銀擬領投 300 億美元，亞馬遜和英偉達可能各投 500 億及 300 億美元，微軟擬投數十億美元。本輪融資是 OpenAI 自去年秋季公司制改革以來的首 | [Link](https://longbridge.com/en/news/276298180.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.